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TO THE EDITOR
The phosphatidylinositol 3-kinase
(PI3K) pathway plays an important role
in regulating cellular growth, prolifera-
tion, survival, and migration. The PI3K
complex is a direct target of activated
RAS (Rodriguez-Viciana et al., 1994)
and is negatively regulated by the lipid
phosphatase phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase (PTEN)
(Stambolic et al., 1998; Stahl et al.,
2003). The PI3K complex phosphory-
lates and activates the v-akt murine
thymoma viral oncogene homologs
(AKT) (Franke et al., 1997), which are
activated in many melanomas and
associated with poor prognosis (Dhawan
et al., 2002). Common routes to PI3K
pathway activation in melanoma are
mutation of neuroblastoma ras viral
oncogene homolog (NRAS) (Albino
et al., 1989; vanElsas et al., 1996) and
deletion or mutation of PTEN (Herbst
et al., 1994; Guldberg et al., 1997;
Bastian et al., 1998; Robertson et al.,
1998; Pollock et al., 2002). PTEN
inactivation is frequent in melanomas
with mutation of BRAF, but not in
melanomas with mutation of NRAS
(Tsao et al., 2004; Curtin et al., 2005),
suggesting that activation of the PI3K
pathway cooperates with genetic altera-
tions of the mitogen-activated protein
kinase pathway in melanoma. In our
previous study some melanomas
showed increased expression levels
of phospho-AKT but did not show
mutations in NRAS or loss of PTEN
(Curtin et al., 2005), suggesting that
additional genetic aberrations may
be present upstream of AKT in the
PI3K pathway. Recent reports indicate
that phosphatidylinositol 3-kinase, cata-
lytic, alpha (PIK3CA) is frequently
mutated in other cancers (Samuels
et al., 2004). We sought to assess the
mutational status of components of the
PI3K complex in a panel of 118 primary
melanomas and in 34 melanoma cell
lines.
We analyzed DNA extracted from
archival paraffin-embedded primary
melanomas with an invasive compo-
nent in which tumor cells predomi-
nated over stroma cells that in part
were previously analyzed and reported
(Curtin et al., 2005). The study was
approved by the Institutional Review
Board of the University of California,
San Francisco. The study compared
DNA from tumors selected to obtain
five groups of comparable sizes: 34
acral melanomas from the palms, soles,
and subungual sites; 17 mucosal mela-
nomas; 13 desmoplastic melanomas;
26 melanomas from chronically sun-
damaged skin and 28 melanoma from
skin without chronic sun damage (non-
chronically sun-damaged skin). Chroni-
cally sun-damaged skin was defined by
the microscopic presence or absence of
marked solar elastosis of the dermis
surrounding the melanomas. In all but
a few cases, chronically sun-damaged
skin melanoma occurred on the face
and non-chronically sun-damaged skin
melanoma occurred on the trunk and
extremities.
Exons of interest were amplified by
PCR and sequenced as described pre-
viously (Curtin et al., 2005) using
Abbreviations: AKT, v-akt murine thymoma viral oncogene homolog; PI3K, phosphatidylinositol
3-kinase; PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha; PIK3CB, phosphatidylinositol 3-kinase,
catalytic, beta; PIK3CD, phosphatidylinositol 3-kinase, catalytic, delta; PIK3R1, phosphatidylinositol
3-kinase, regulatory, 1; PIK3R2, phosphatidylinositol 3-kinase, regulatory, 2; PIK3R3, phosphatidylino-
sitol 3-kinase, regulatory, 3; PTEN, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase; NRAS,
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specific primers (Table 1). We se-
quenced the helical (exon 9) and kinase
domain (exon 20) of PIK3CA in 118
primary melanomas since these exons
contain the majority (82–90%) of muta-
tions in other cancers (Samuels et al.,
2004). In addition, the entire coding
region of PIK3CA (Table 1) was ampli-
fied and sequenced using cDNA from a
previously described panel of 34 mel-
anoma cell lines (Pavey et al., 2004)
wild type for PTEN. We also analyzed
targeted regions of the other compo-
nents of PI3K, which is a heterodimer
composed of one of three 110 kD
catalytic subunits (encoded by PIK3CA,
phosphatidylinositol 3-kinase, catalytic,
beta (PIK3CB), and phosphatidylinositol
3-kinase, catalytic, delta (PIK3CD)
combined with one of the three reg-
ulatory subunits (encoded by phospha-
tidylinositol 3-kinase, regulatory, 1
(PIK3R1), phosphatidylinositol 3-ki-
nase, regulatory 2 (PIK3R2), and phos-
phatidylinositol 3-kinase, regulatory, 3
(PIK3R3). We sequenced exons 12, 13,
14, and 15 of PIK3R1, exons 12, 13,
and 14 of PIK3R2 and exons 7, 8, and
10 of PIK3R3 in 81 of the primary
melanoma samples since mutations
have been reported in the C terminal
SH2 domain of PIK3R1 (Cuevas et al.,
2001; Philp et al., 2001; Jucker et al.,
2002). ‘Hotspots’ where mutations in
PIK3CA have been previously noted
(Samuels et al., 2004) were amplified
by PCR in the PIK3CB and PIK3CD
genes. These exons corresponded to
exons 11 and 23 for PIK3CB and exons
11 and 22 for PIK3CD.
Sequence analysis of PIK3CA in 118
primary melanomas and in 34 melano-
ma cell lines wild type for PTEN
revealed one somatic C to T mutation
(P539L) in a primary melanoma, one
somatic G to A mutation (E970K), two
silent variants (I121I, F139F), and a
common (10%) novel germline poly-
morphism (I391M) among the cell lines
(Table 2). The P539L substitution has
not been reported previously, however,
a P539R substitution was reported in
breast cancer (Samuels et al., 2004).
The melanoma with the P539L muta-
tion showed increased phospho-AKT
protein levels by immunohistochemis-
try (Curtin et al., 2005) but did not have
mutations of BRAF, NRAS, HRAS, or
Table 1. Primers used for amplification and sequencing of PI3K subunits
Primer name Primer sequence
Annealing
temperature (1C)1 Product size
PIK3CAex9F1 ggggaaaaatatgacaaagaaa 61–57 2492
PIK3CAEx9R1 tgagatcagccaaattcagtt
PIK3CAex20F acagcatgccaatctcttcat 57–50 2092
PIK3CAex20R tgtgtggaagatccaatccat
PIK3R1ex12F ccgttcctgatgtacccaga 61–57 2832
PIK3R1ex12R cctgaattgtagcaatcaccaa
PIK3R1ex13F ccagctgagaaagacgagaga 61–57 2632
PIK3R1ex13R agcaagtcatgcattttcctaa
PIK3R1ex14F tgatggctcctgcactctt 61–57 2992
PIK3R1ex14R cccccaaaactcaatgaatg
PIK3R1ex15F cccaagttgagactgcacaa 56–50 2902
PIK3R1ex15R cgcctctgctgtgcatatact
PIK2R2ex12F caggagtttgagggtgcagt 61–57 3462
PIK2R2ex12R gccacttggtggagagagag
PIK2R2ex13F acccagaaccctctctcctc 56–50 2832
PIK2R2ex13R caacttttcctccctggtga
PIK2R2ex14F tcaccagggaggaaaagttg 56–50 3982
PIK2R2ex14R ggcaggcattcaatgagag
PIK3R3ex7F gaccgtgctcacccagtag 56–50 3332
PIK3R3ex7R tctcttcttccacctctagtgtctc
PIK3R3ex8F tgggattaggaaaaacaagagg 56–50 2942
PIK3R3ex8R tcctcaagtgacaatgacaacc
PIK3R3ex10F tctggccatttagtgtcctttt 61–57 2902
PIK3R3ex10R cacctctcttcccacttcctc
M13F tgtaaaacgacggccagt3
M13R agcggataacaatttcacacagg
PIK3CA1F caatgcctccaagaccatcatc 65–57 748 bp4
PIK3CA1R ttgccctgatattctaaaacac
PIK3CA2F ctccaaataatgacaagcagaag 65–57 757 bp4
PIK3CA2R ccatgaggtactggccaaag
PIK3CA3F gctctgttaaaggccgaaag 65–57 751 bp4
PIK3CA3R gctttcttcagtaaaaatctcac
PIK3CA4F gtatttaattcagctagtacaggtc 65–57 755 bp4
PIK3CA4R tgagccactgatgtagtgtgtg
PIK3CA5F ctgtcaatcggtgactgtgtg 65–57 773 bp4
PIK3CA5R gcaatcggtctttgcctgc
PIK3CB11F gagattgcaagcagtgatagtg 65–55 251 bp4
PIK3CB11R ttaggccaaatctgaagcag
PIK3CB23F ggatgcatatctgattttacgac 65–55 242 bp4
PIK3CB23R agtctttccgaactgtgtgg
PIK3CD11F tggagaagatcttggagctg 65–55 244 bp4
PIK3CD11R cacagcaggtagagcatctgg
Table 1 continued on the next page
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KRAS and retained a normal number of
copies of the PTEN locus by array
comparative genomic hybridization
(GEO, http://www.ncbi.nlm.nih.gov/geo/),
accession number GSE2631) (Curtin
et al., 2005), indicating that the mutation
may activate the PI3K pathway in this
melanoma. Our data show that unlike in
carcinomas, mutation of PIK3CA is rare
in melanoma.
Amplification of a gene is an alter-
native mechanism for oncogenic acti-
vation. Activation of PIK3CA by
amplification is commonly found in
gastric cancer resulting in increased
expression of PIK3CA with subsequent
elevated levels of phospho-AKT (Byun
et al., 2003). Our comparative genomic
hybridization data did not indicate
amplification of PIK3CA or any other
PI3K subunit in primary melanomas
(Bastian et al., 1998; Curtin et al.,
2005). Sequencing of the inter-SH2
region and the terminal C2 domains of
PIK3R1, PIK3R2, and PIK3R3 in 81
primary melanomas uncovered one
variant (N317S) in PIK3R3 that was
also present in normal tissue from this
individual. The polymorphism occurred
in a patient with an acral primary
melanoma without a mutation of NRAS
and/or PTEN loss as detected by array-
comparative genomic hybridization
(Curtin et al., 2005). We observed very
low levels of phospho-AKT by immu-
nohistochemistry indicating that the
PI3K pathway in this sample is not
strongly activated. No mutations were
found in the catalytic subunits PIK3CB
and PIK3CD in 15 melanoma cell lines.
We observed a silent polymorphism
(T926T) in PIK3CD with an allele
frequency of 10%.
Our findings indicate that, unlike
NRAS and PTEN, members of the PI3K
family are rarely subject to somatic acti-
vation in melanoma. Additional studies
are warranted to identify how the PI3K
pathway is activated in melanomas
without aberrations in PTEN or RAS.
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